Építés alatt – nem éles oldal
Belépés
Leállítva2. fázis

Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer

A legfontosabb adatok

Ki végzi
University Health Network, Toronto
Hol
Kanada1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Leállítva
Fázis
2. fázis
Résztvevők
5 fő vett részt
Kezdés
2022. jan. 24.
Befejezés
2025. febr. 19.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • cfDNA blood test
  • Nivolumab
  • Ipilimumab
  • Platinum-based Chemotherapy
A regiszteradat frissítve
2026. január 8.
Miért állt le
Low accrual

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 29 feltétel megnézéseKevesebb

Ki vehet részt

  • Age ≥ 18 years at the time of screening or age of consent
  • Written informed consent obtained from the subject prior to performing any protocol-related procedures, including screening evaluations
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Weight ≥ 35 kg
  • Must have a life expectancy of at least 12 weeks
  • Recurrent or newly diagnosed metastatic non-small cell lung cancer
  • Tumor PDL1 status <50%
  • Non-Squamous and squamous histologies are eligible
  • Histologies with targetable mutations (EGFR, ALK, ROS1) are not eligible, regardless of prior treatment with tyrosine kinase inhibitors
  • No prior radiation, surgery or chemotherapy is allowed for the current diagnosis of non-small cell lung cancer
  • Adequate organ and marrow function

Ki nem vehet részt

  • Receipt of any conventional or investigational anticancer therapy within 21 days or palliative radiotherapy within 14 days prior to the scheduled first dose of study treatment
  • Prior receipt of any immune-mediated therapy
  • Incomplete surgical resection
  • Concurrent enrolment in another therapeutic clinical study. Enrolment in observational studies will be allowed
  • Any toxicity (excluding alopecia) from prior standard therapy that has not been completely resolved to baseline at the time of consent
  • Participants with prior history of myocardial infarction, transient ischemic attack, congestive heart failure ≥ Class 3 based on New York Heart Association Functional Classification or stroke within the past 3 months prior to the scheduled first dose of study treatment
  • Active or prior documented autoimmune disorders within the past 3 years prior to the scheduled first dose of study treatment with exceptions
  • Known allergy or hypersensitivity to investigational product formulations
  • Current or prior use of immunosuppressive medication within 14 days prior to the scheduled first dose of study treatment with exceptions
  • Receipt of live, attenuated vaccine within 30 days prior to the scheduled first dose of study treatment - Major surgery within 28 days prior to scheduled first dose of study treatment or still recovering from prior surgery
  • Any condition that, in the opinion of the investigator, would interfere with safe administration or evaluation of the investigational products or interpretation of subject safety or study results
  • Participants with confirmed human immunodeficiency virus (even if viral load is undetectable), chronic or active hepatitis B or C, or active hepatitis A
  • History of primary immunodeficiency, solid organ transplantation, or active tuberculosis (by clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice)
  • Other invasive malignancy within 2 years. Non-invasive malignancies (i.e., cervical carcinoma in situ, in situ prostate cancer, non-melanomatous carcinoma of the skin, ductal carcinoma in situ of the breast that has been surgically cured) are excluded from this definition
  • History of more than one event of infusion related reactions requiring permanent discontinuation of intravenous drug treatment
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection requiring antibiotic therapy, uncontrolled hypertension, bleeding diatheses, or psychiatric illness/social situations that would limit compliance with study requirements, substantially increase risk of incurring adverse events, or compromise the ability of the subject to give written informed consent
  • Females who are pregnant, lactating, or intend to become pregnant during their participation in the study
  • Participants who are involuntarily incarcerated or are unable to willingly provide consent or are unable to comply with the protocol procedures

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this research study is to look at how effective two drugs, nivolumab and ipilimumab, are for people with non-small lung cancer that has metastasized (has spread to other parts of the body) and to see what effects these drugs have on these tumors.

A vizsgálat csoportja

  • Non-Small cell Lung CancerA vizsgált kezelés

    Nivolumab, intravenously (given by vein), once every 3 weeks Ipilimumab, intravenously (given by vein), once every 6 weeks Participants will have blood samples taken for cell free deoxyribonucleic acid (cfDNA) testing. If there is an increasing or stable tumor cfDNA, platinum-doublet chemotherapy will be given.

    Kezelés: cfDNA blood test, Nivolumab, Ipilimumab és Platinum-based Chemotherapy

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Beyond Chemotherapy: Nivolumab-Ipilimumab With cfDNA-guided Treatment Intensification as a Chemotherapy-sparing Strategy in Metastatic Non-small Cell Lung Cancer
A regiszteradat frissítve
2026. január 8.